A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3
- Conditions
- HIV Infections
- Registration Number
- NCT00002123
- Lead Sponsor
- Pharmacia and Upjohn
- Brief Summary
To evaluate the safety, tolerance, pharmacokinetics, and efficacy of delavirdine mesylate (U-90152S) in combination with didanosine (ddI) versus ddI alone in HIV-positive patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (84)
Univ of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
East Bay AIDS Ctr
🇺🇸Berkeley, California, United States
California Med Research Group
🇺🇸Fresno, California, United States
Los Angeles County - USC Med Ctr
🇺🇸Los Angeles, California, United States
Los Angeles County / Health Research Assoc / Drew Med Ctr
🇺🇸Los Angeles, California, United States
CARE Ctr / UCLA Med Ctr
🇺🇸Los Angeles, California, United States
UCI Med Ctr
🇺🇸Orange, California, United States
AIDS Community Research Consortium
🇺🇸Redwood City, California, United States
UCD Med Ctr / AIDS and Related Disorders Clinic
🇺🇸Sacramento, California, United States
St Lukes Medical Group
🇺🇸San Diego, California, United States
Scroll for more (74 remaining)Univ of Alabama at Birmingham🇺🇸Birmingham, Alabama, United States